In response to a call for comment on the proposed New York Office of Cannabis Management symbol, the Doctors for Cannabis Regulation submitted a letter outlining the design flaws of the proposed symbol and recommended adopting the International Intoxicating Cannabinoid Product Symbol instead.
In a recent press release (1), Doctors for Cannabis Regulation (DFCR) published their letter sent to the New York State Cannabis Control Board (CCB) and the New York Office of Cannabis Management (OCM). “The DFCR is the global voice for physicians and other health professionals to advance the legalization and science-based regulation of cannabis,” explained the introduction. In the letter, the DFCR explained why New York should adopt the International Intoxicating Cannabinoid Product Symbol (IICPS) on all cannabis products sold in the state. In addition, 22 other cannabis organizations signed their support and three states—Montana, Vermont, and New Jersey—have already adopted the IICPS.
“The IICPS was developed through a collaboration between DFCR and ASTM International, meeting a list of requirements including being able to simply communicate a public health message of ‘Caution with Cannabis,’ using the simplest possible design to fit within an allotted space and incorporating a symbol that transcends age, language, culture, literacy, and knowledge of cannabis and the Latin alphabet,” said the DFCR in the letter (1).
The DFCR listed the following as the main flaws of the symbol proposed by the OCM (1):
More on the IICPS can be found in an article published in Cannabis Science and Technology. Last year, founder and past president of DFCR Dr. David Nathan along with product designer Eli Nathan, contributed an in-depth explanation of the formulation and implementation of the IICPS. “We present the IICPS to regulators with a simple message: This is not just the right choice as a universal symbol for cannabis products—it’s also the safe choice,” concluded the co-designers of the IICPS (2).
References
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.